Literature DB >> 21468069

The prevention of colitis-related cancer by 5-aminosalicylates: an appealing hypothesis that remains unproven.

Jonathan P Terdiman.   

Abstract

Whether or not 5-aminosalicylates can prevent colorectal cancer among patients with colitis remains an open question. The observational studies examining this question have provided conflicting results, but none of these studies have been of sufficient quality to provide a definitive answer one way or another.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21468069     DOI: 10.1038/ajg.2011.56

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  4 in total

Review 1.  Mesalamine in the treatment and maintenance of remission of ulcerative colitis.

Authors:  Maggie Ham; Alan C Moss
Journal:  Expert Rev Clin Pharmacol       Date:  2012-03       Impact factor: 5.045

Review 2.  Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management.

Authors:  Parambir S Dulai; William J Sandborn; Samir Gupta
Journal:  Cancer Prev Res (Phila)       Date:  2016-09-27

Review 3.  Does aspirin or non-aspirin non-steroidal anti-inflammatory drug use prevent colorectal cancer in inflammatory bowel disease?

Authors:  Nick E Burr; Mark A Hull; Venkataraman Subramanian
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

4.  Influence of myeloperoxidase on colon tumor occurrence in inflamed versus non-inflamed colons of Apc(Min/+) mice.

Authors:  Mazin Al-Salihi; Ethan Reichert; F A Fitzpatrick
Journal:  Redox Biol       Date:  2015-07-29       Impact factor: 11.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.